MCET (MultiCell Technologies) EBITDA Margin %: -87.69% (As of Aug. 2015)


What is MultiCell Technologies EBITDA Margin %?

MultiCell Technologies MCET -90.00% EBITDA Margin % is -87.69% as of Aug. 2015.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. MultiCell Technologies's EBITDA for the three months ended in Aug. 2015 was $-0.17 Mil. MultiCell Technologies's Revenue for the three months ended in Aug. 2015 was $0.20 Mil. Therefore, MultiCell Technologies's EBITDA margin for the quarter that ended in Aug. 2015 was -87.69%.

MultiCell Technologies  (OTCPK:MCET) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

MultiCell Technologies EBITDA Margin % Related Terms

MultiCell Technologies EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for MultiCell Technologies's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MultiCell Technologies EBITDA Margin % Chart

MultiCell Technologies Annual Data
Trend Nov05 Nov06 Nov07 Nov08 Nov09 Nov10 Nov11 Nov12 Nov13 Nov14
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,254.55 -3,932.65 -2,755.10 -2,789.80 -1,057.14

MultiCell Technologies Quarterly Data
Nov10 Feb11 May11 Aug11 Nov11 Feb12 May12 Aug12 Nov12 Feb13 May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,675.00 -183.33 -2,333.33 37.88 -87.69

MCET vs ERGO, OPLI, GLAG: EBITDA Margin % Comparison

For the Biotechnology subindustry, MultiCell Technologies's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MultiCell Technologies EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MultiCell Technologies's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where MultiCell Technologies's EBITDA Margin % falls into.


MultiCell Technologies EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

MultiCell Technologies's EBITDA Margin % for the fiscal year that ended in Nov. 2014 is calculated as

EBITDA Margin %=EBITDA (A: Nov. 2014 )/Revenue (A: Nov. 2014 )
=-0.518/0.049
=-1,057.14 %

MultiCell Technologies's EBITDA Margin % for the quarter that ended in Aug. 2015 is calculated as

EBITDA Margin %=EBITDA (Q: Aug. 2015 )/Revenue (Q: Aug. 2015 )
=-0.171/0.195
=-87.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -87.69% mean?
MultiCell Technologies (MCET) has a EBITDA Margin % of -87.69% as of Aug. 2015. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on MultiCell Technologies and its competitors.
Is MultiCell Technologies' EBITDA Margin % too high?
MultiCell Technologies' current EBITDA Margin % is -87.69%.
How does MultiCell Technologies' EBITDA Margin % compare to ERGO and OPLI?
MultiCell Technologies' EBITDA Margin % of -87.69% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on MultiCell Technologies and its competitors. MultiCell Technologies's current EBITDA Margin % is -87.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MultiCell Technologies stock overvalued right now?
MultiCell Technologies (MCET) has a current EBITDA Margin % of -87.69%. The current EBITDA Margin % is -87.69%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For MultiCell Technologies (MCET), the current EBITDA Margin % is -87.69% as of Aug. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MultiCell Technologies Business Description

Address 4144 North Central Expressway, Suite 600, Dallas, TX, USA, 75204
MultiCell Technologies Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and others. Its therapeutic development platform includes several patented techniques used to isolate, characterize, and differentiate stem cells from the human liver or control the immune response at transcriptional and translational levels through dsRNA-sensing molecules, such as Toll-like receptor, RIG-I-like receptor, and MDA-5 signaling. The company's medical device development platform is based on the design of a next-generation bioabsorbable stent, the Ideal BioStent, for interventional cardiology and peripheral vessel applications. All the operations are functioned within United States.